Difference between revisions of "Team:DTU-Denmark/Integrated Human Practices"
| Line 181: | Line 181: | ||
| + | <!-- Image Map Generated by http://www.image-map.net/ --> | ||
| + | <img src="https://static.igem.org/mediawiki/2019/9/91/T--DTU-Denmark--iHPmain.png" border="0" width="800" height="944" orgWidth="800" orgHeight="944" usemap="#integratedhpfig3"> | ||
| + | <map name="integratedhpfig3"> | ||
| + | <area target="" alt="Zymergen" title="Zymergen" href="#zymergen" coords="327,772,105" shape="circle"> | ||
| + | <area target="" alt="Zymergen" title="Zymergen" href="#zymergen" coords="344,504,43" shape="circle"> | ||
| + | <area target="" alt="Peter Richards" title="Peter Richards" href="#peterR" coords="115,582,106" shape="circle"> | ||
| + | <area target="" alt="Peter Richards" title="Peter Richards" href="#peterR" coords="296,450,39" shape="circle"> | ||
| + | <area target="" alt="Novozymes" title="Novozymes" href="#novo" coords="100,303,107" shape="circle"> | ||
| + | <area target="" alt="Novozymes" title="Novozymes" href="#novo" coords="371,402,48" shape="circle"> | ||
| + | <area target="" alt="Bolt Threads" title="Bolt Threads" href="#boltt" coords="304,316,43" shape="circle"> | ||
| + | <area target="" alt="Bolt Threads" title="Bolt Threads" href="#boltt" coords="286,104,105" shape="circle"> | ||
| + | <area target="" alt="Jens Frisvad" title="Jens Frisvad" href="#jensf" coords="562,132,107" shape="circle"> | ||
| + | <area target="" alt="Jens Frisvad" title="Jens Frisvad" href="#jensf" coords="407,329,39" shape="circle"> | ||
| + | <area target="" alt="Jakob Blæsbjerg" title="Jakob Blæsbjerg" href="#jakobb" coords="482,395,50" shape="circle"> | ||
| + | <area target="" alt="Jakob Blæsbjerg" title="Jakob Blæsbjerg" href="#jakobb" coords="696,364,104" shape="circle"> | ||
| + | </map> | ||
| + | |||
| + | |||
| + | |||
| + | |||
| + | |||
| + | |||
| + | |||
| + | <div class="modal fade" id="zymergen" tabindex="10" role="dialog" aria-labelledby="agencies" aria-hidden="true" style="z-index: 1000"> | ||
| + | <div class="modal-dialog modal-dialog-centered" role="document"> | ||
| + | <div class="modal-content"> | ||
| + | <div class="modal-header"> | ||
| + | <h5 class="modal-title" id="exampleModalLongTitle">Influences from the market</h5> | ||
| + | <button type="button" class="close" data-dismiss="modal" aria-label="Close"> | ||
| + | <span aria-hidden="true">×</span> | ||
| + | </button> | ||
| + | </div> | ||
| + | <div class="modal-body"> | ||
| + | <p>There are different types of wastewater treatment plants, and we had the opportunity to both meet municipal as well as private plants. Process engineer <b>Peter Gruvstedt from the private plant at AstraZeneca</b> thought that Biotic Blue could be implemented in their fungal process step of purification, if an additional system was built on the side of the compartment, and if the enzyme was optimized for their pharmaceuticals. AstraZeneca’s treatment plant was especially interesting for Biotic Blue since the pH of the fungal treatment is optimal for the enzyme as well as a controlled temperature.</p> | ||
| + | <img class="contImg" src="https://static.igem.org/mediawiki/2018/0/07/T--Stockholm--Astrazeneca.jpg"> | ||
| + | |||
| + | <h5><i>"This could reduce the amount of sulfamethoxazole in both WWTP effluents, the wastewater and the sludge."</i> - Pharem Biotech</h5> | ||
| + | <p>Meeting with the CEO <b>Martin Ryen</b> and <b>Domenico Palumberi</b> from Pharem, we had the opportunity to pitch our idea - Biotic Blue. Pharem produces enzymes for treating Swedish wastewater, and they both gave us useful advice and insights in the lab procedure. Martin, the founder and CEO of Pharem thought that it would be feasible to incorporate Biotic Blue before the biological treatment of wastewater since it would reduce the risk of triggering antibiotic resistance. After our meeting, we got back to revise our product implementation and discuss in which location our vision makes the biggest impact. </p> | ||
| + | <img class="contImg" src="https://static.igem.org/mediawiki/2018/2/2c/T--Stockholm--pharemm2.jpg"> | ||
| + | |||
| + | </div> | ||
| + | </div> | ||
| + | </div> | ||
| + | </div> | ||
| Line 265: | Line 309: | ||
</div></div> | </div></div> | ||
| + | <script src="/Template:DTU-Denmark/mapresizer?action=raw&ctype=text/javascript"></script> | ||
| + | <script> | ||
| + | imageMapResize(); | ||
| + | |||
| + | |||
| + | </script> | ||
</html> | </html> | ||
Revision as of 22:53, 20 October 2019
Integrated Human Practices
A huge goal for our project has been to secure that it has the biggest impact possible. This has meant that we have been in contact with important stakeholders and their advice has shaped our approach and the path of the project.
Being the number one group of organism to industrially produce enzymes, filamentous fungi are exceptionally important to the everyday lives of many people even though they might not notice it.
LEAP started as a reaction to the extreme lack of resources to work with filamentous fungi and attempted to use synthetic biology to contribute to the list of tools necessary to work with these organisms.
Originally, the project aimed to make a promoter library for either filamentous fungi, yeast, moss, or maybe all three, but following discussions with several companies and scientists, the team decided to develop a software that enabled the creation of promoters that could be applied to any organism and tested the function of the software in Aspergilli.
Stakeholder Analysis
In March, the team looked into the impacts of the project on different stakeholders and therefore made a stakeholder analysis, as shown in figure 2.
This stakeholder analysis reveals that companies such as Novozymes, Zymergen, and Bolt Threads are among the most important to our project, both in interest and power. This means that their opinions should be managed closely. Additionally, researchers such as Jens Frisvad (DTU, Denmark), Jakob Blæsbjerg (DTU, Denmark), and Peter Richard (VTT, Finland) could benefit from our project, making them important stakeholders. Although other iGEM teams do not have a lot of power, their interest could nevertheless be great and they should, therefore, be well informed.
The public and the DTU BlueDot program will most likely not take much interest in the project as a promoter library can be a very technical concept and not immediately usable by non-specialists. However, as DTU BlueDot is a big sponsor of the team, they are important to keep satisfied.
Based on the stakeholder analysis, we decided to contact three different biotech companies; Novozymes, Zymergen, and Bolt Threads as all three companies work with genetically modified filamentous fungi. We asked them how our project could influence their work and for suggestions regarding the experiment.
We also reached out to several scientists, including Jakob Blæsbjerg from DTU and Peter Richard from VTT (Technical Research Centre) in Finland. They helped provide us with protocols and advice on how to grow the fungi and how to ensure reproducible and comparable results.
Even though the public is neither very powerful nor interested in the project according to our stakeholder analysis, we nevertheless decided to contact high schools in order to talk to young people about synthetic biology and its aspects as well as about our project and what good it can do in the world. We also partook in several events: The annual UNF (Ungdommens Naturvidenskabelige Forening) Biotech Camp; Science Expo, a large science fair in Copenhagen; and the annual Biotech Academy Camp in order to increase their knowledge and interest in a topic like synthetic biology. This is described further on Education and Engagement.
